← Eichor
Condition: Immunocompromised Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Immunocompromised

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic H
Phase N/A · 1 location(s) · Antonello Di Paolo, M.D., Ph.D. · NCT07013370Detection of Azole Resistance Inducing Mutations on DNA Extracted Directly From Serum or Plasma of Immunocompromised Pat
Phase N/A · 1 location(s) · Bart Rijnders · NCT06069505Study of a Cohort of Non-HIV Immunocompromised Patients With Toxoplasmosis at the Strasbourg University Hospital
Phase N/A · 1 location(s) · University Hospital, Strasbourg, France · NCT07299500Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune Syst
Phase 2 · 38 location(s) · National Cancer Institute (NCI) · NCT07042295COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
Phase 2 · 3 location(s) · McGill University Health Centre/Research Institute of the Mc · NCT06599658A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and th
Phase 2 · 37 location(s) · GlaxoSmithKline · NCT07092865Shingrix in Renal Transplant Recipients
Phase 3 · 4 location(s) · University of Colorado, Denver · NCT04128189Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
Phase 3 · 28 location(s) · Ansun Biopharma, Inc. · NCT03808922The Effect of Echinacea (Immulant ®) in the Treatment of CRYPTOSPORIDIOSIS in Immunocompromised Children
Phase 2 · 1 location(s) · Al-Azhar University · NCT07388615Personalized Immunological Score for the Prediction of Severe Infectious Events in Immunocompromised Patients and Tailor
Phase N/A · 1 location(s) · Fondazione IRCCS Policlinico San Matteo di Pavia · NCT07379554A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
Phase 3 · 148 location(s) · Pfizer · NCT07013474Third Party Viral Specific T-cells (VSTs)
Phase 2 · 4 location(s) · Children's Hospital Medical Center, Cincinnati · NCT02532452Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients
NA · 11 location(s) · Alpha Tau Medical LTD. · NCT06615635Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts
Phase 1 · 3 location(s) · Children's National Research Institute · NCT04691622Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus S
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT05101213Treatment of BK Virus Infection With CTL Cells in Immunocompromised Transplant Patients
EARLY_Phase 1 · 1 location(s) · Children's Hospital of Philadelphia · NCT04293042Individualised Dose Optimisation of Ganciclovir in Immunocompromised Children Trial (ID-MAGIC)
Phase 2 · 7 location(s) · Murdoch Childrens Research Institute · NCT06574789BioMArkeRs of INflammation, Infection, and Immunity in the Critical Area (MARINA): the Use of Inflammatory and Immunity
Phase N/A · 1 location(s) · University of Turin, Italy · NCT07682766T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients
Phase 1 · 2 location(s) · Children's National Research Institute · NCT05141058Viral Infections in Healthy and Immunocompromised Hosts
Phase N/A · 1 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT01306084Analysis of the Specificity and Persistence of Nasal Immune Responses to Respiratory Viral Antigens in Immunocompromised
Phase N/A · 1 location(s) · Fondazione IRCCS Policlinico San Matteo di Pavia · NCT07295535Vaccine-induced Immunity in Immunocompromised Patients
Phase N/A · 1 location(s) · University of Cologne · NCT06612515Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
Phase 2 · 3 location(s) · Fred Hutchinson Cancer Center · NCT06817889Cologne Cohort of Neutropenic Patients (CoCoNut)
Phase N/A · 1 location(s) · University Hospital of Cologne · NCT01821456Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia
Phase 3 · 1 location(s) · Todd C. Lee MD MPH FIDSA · NCT04851015Expansion of Virus-Specific Lymphocytes for Cell Therapy
Phase 1 · 1 location(s) · Hospital Israelita Albert Einstein · NCT06011486OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients
Phase 2 · 4 location(s) · Calmy Alexandra · NCT07406217Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04712539OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Tri
Phase 2 · 18 location(s) · ANRS, Emerging Infectious Diseases · NCT05587894Immunosuppression and Intensive Care Unit-acquired Multidrug-resistant Bacteria
Phase N/A · 1 location(s) · University Hospital, Lille · NCT06652126
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.